A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost

• Main Authors: Prasert Thongcharoen, Vinai Suriyanon, Robert M. Paris, Chirasak Khamboonruang, Mark S. De Souza, Silvia Ratto-Kim, Chitraporn Karnasuta, Victoria R. Polonis, Lynn Baglyos, Raphaelle El Habib, Sanjay Gurunathan, Susan Barnett, Arthur E. Brown, Deborah L. Birx, John G. McNeil, Jerome H. Kim
• Format: Journal
• Published: 2018
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=34848908400&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/61274
• Institution: Chiang Mai University

BACKGROUND: The development of an effective HIV-1 vaccine is critical to control the pandemic. A prime-boost HIV-1 vaccine trial assessing safety and immunogenicity was conducted in Thailand as part of an evaluation of candidate regimens for a phase 3 efficacy trial. METHODS: ALVAC-HIV (vCP1521), ex...